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registering a growth of about 29% over the last year.[1,2] 
This is shown in Figure 1. 
The exports of drugs, pharmaceuticals and fine chemicals 
from India have grown at a compounded annual growth 
rate (CAGR) of 17.8% during the five-year period 2003-04 
to 2007-08.[1] The share of pharma exports to total exports 
is 2% over the last 12 years.[3]
Need of the hour
Traditionally, larger pharmaceutical markets like the US, 
Europe have been the prime target markets for Indian 
pharma companies. But since the last few years, there has 
been a remarkable depression in the export profile of India 
to these countries. The export of pharmaceuticals to the 
US has drastically declined at the rate of 36.8%.[4] 
INTRODUCTION
Indian Pharmaceutical export: present scenario
The Indian pharmaceutical industry, which is one of the 
major manufacturers of multi-source generic drugs, has a 
broad spectrum of export of pharmaceuticals all over the 
world. The exports of drugs, pharmaceuticals, and fine 
chemicals for the year 2008-09 stood at US $ 8.6 billion, 
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At the same time the other destinations of export are not 
only yielding the same ratio of profit but are also increasing 
at an appreciable rate. Many new windows for trade are 
opening for India. For example, export to African countries 
has increased from 10-15% in the year 2007-08.[5] 
Therefore, it is time to look at other segments of the market 
which is by and large called ‘emerging market’ and can 
increase our export rate including our traditional customers.
GULF COOPERATION COUNCIL[6]
Export opportunities for India:[7]
Based on responses from 215 representatives of leading 
pharmaceutical manufacturers in India and those registered 
in the six GCC countries, the FICCI study found an 
overwhelming keenness to tap the GCC market.
According to a FICCI survey report “There is a 
Figure 1: Statistics on Indian pharmaceutical exports 
[Source: Singh S, Drugs Regulatory Reforms & Policy Initiatives- India accessed 
http://www.assocham.org/7km2009/presentations/Day_2_27_11_09/Surinder_
Singh_DCGI.pdf]
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considerable scope for increasing our exports of drugs and 
pharmaceutical products to GCC countries, namely Saudi 
Arabia, Kuwait, Bahrain, Qatar, United Arab Emirates and 
Sultanate of Oman [Tables 1 and 2].”
New juncture
Gulf  Cooperation Council regulatory authorities
Gulf Central Committee for Drug Registrations   
(GCC-DR)
•  Approved in May 1999.
•  Located in the executive office for Health Ministers, 
Riyadh, Saudi Arabia.
Drug registration: there are two processes of drug 
registration;
A. Centralized registration procedure
B.  Decentralized registration procedure
A. Centralized registration procedure:[21]
1.  The executive office of GCC-DR assumes the receipt 
of registration files after ensuring the fulfillment of 
registration requirements and upon duly filling the 
following forms:
•  The drug companies’ registration form.
•  A pharmaceutical chemical entity/ preparation 
registration form.
2.  Eight complete files for each chemical entity and 17 
samples have to be submitted to the executive office 
and two samples shall be dispatched to each country 
along with registration file.
3.  Every country shall study the registration files forwarded 
to it and then return those files with its recommendation 
to the committee. The procedure is shown in Figure 2.
4.  The company needs to provide the laboratory for the 
analysis of standard materials, methods etc.
5.  The executive office dispatches the samples of chemical 
entity to reference-accredited laboratory for the analysis.
Table 1: General information about the Gulf 
Cooperation Council countries
Member states 1.  Saudi Arabia
2. Kuwait
3. Oman 
4. Bahrain
5. Qatar 
6.  United Arab Emirates
Demographics •  Total population estimated at 45 million inhabitants
•  The GCC is a cooperation organization having 
different domains including health
•  The various councils of ministers of the participating 
countries meet twice a year to discuss existing and 
new cooperation issues
Table 2: Opportunities in the Gulf Cooperation Council 
market
•  GCC countries- 80% demand of pharmaceuticals through import
•  Indian export to GCC countries- 119.25 USD billion (2002-03) 
•  Largest trading partner after US - 6.8 USD billion business annually[7]
•  Annual increase of population is more than one million - Great 
potential for healthcare sector
•  Economic development boards (EDB), joint ventures and economic 
liberalization by GCC countries- Opportunities for Indian investors[19,20]
•  Less custom duty on pharmaceuticals- duty-free (Saudi Arabia & 
UAE) and 4-5% by all the remaining GCC members.[18]
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6.  After approving the registration of company andor 
chemical entity centrally, the remaining authentication 
and documentation, fees are finalized on country basis, 
as per their prescribed and established policies. The fees 
for centralized  procedure is shown in Table 3. 
7.  The executive office issues the registration certificate.
8.  The companies reserve their rights to lodge their 
grievances to the executive office within a period of two 
months effective from the date of notification about 
the registration by GCC-DR.
Fees
The validity of  the central registration
a.  The central Gulf committee’s resolutions for drug 
registration are binding for the consolidated purchasing.
b.  All countries must sanction and approve the export 
price, which has been approved by the committee 
upon completion of the registration procedures in the 
country.
Issue of Centralization of registration of drugs
It is not mandatory to centralize the registration of drugs 
in GCC, as of now. But for special classes of drugs, 
registration through the centralized process is necessary. 
These are as follows:
1.  Generic drugs for which bioequivalence studies cannot 
be done, e.g. inhalable medicines and some nasal 
inhalers.
2. Drugs supported by biotechnology for which 
bioequivalence studies cannot be done and which 
require clinical or pharmacodynamic studies.
3.  Drugs with narrow therapeutic spectrum, which are 
administered orally.
B. The Decentralized registration procedure:[8]
Registration regulations in major countries of  GCC
Although there is a centralized and quite harmonized 
process for drug registration in GCC countries, the 
regulatory requirements of a few big countries like Saudi 
Arabia and UAE are separate. These countries have their 
well-established regulatory system and its enforcement. 
In this study, we will discuss briefly the registration 
requirements of multi-source generic products of the 
following GCC countries:
1.  Saudi Arabia
2. Bahrain
3.  Kuwait 
4.  UAE
DRUG REGISTRATION REGULATIONS OF THE 
KINGDOM OF SAUDI ARABIA[8-10]
The Saudi Food and Drug Authority [SFDA] is the main 
drug regulatory body of Saudi Arabia. SFDA prefers the 
drug dossier submission in electronic format (eCTD). The 
SFDA has approved more than 6177 drugs of different 
strength and formulations, till May 20, 2010.[11] Drug 
registration requirements and procedure is as follows:
Drug Registration
Online filing of  application
The appropriate application form can easily be downloaded 
from the official website of SFDA i.e.  http://www.sfda.
gov.sa/En/Drug.
Once the application is submitted, a reference number is 
given to the applicant to facilitate communication with 
SFDA.
The applicant is needed to make an appointment with 
the SFDA office to hand over the application. The 
earliest appointment can be scheduled 1 to 12 weeks in 
advance. The applicant can reschedule a week before the 
Figure 2: Components of dossier
Table 3: Fees for drug registration
Company registration Product registration
SR. 5000 which 
shall be the 
50% fee against 
studying the 
company’s file
SR. 5000 which 
shall represent 
50% of remainder 
fee upon the 
final consent and 
approval for their 
registration
SR.3000 which 
shall be 50% of 
registration fee 
against studying 
the company’s file
SR. 3000 which 
shall represent 
50% of remainder 
fee upon the 
final consent and 
approval for their 
registration158   Journal of Young Pharmacists Vol 3 / No 2
appointment. An automatic reminder will be sent 3 days 
before the appointment. Target performance timeline for 
SFDA is shown in Table 4.
Registration process:
Agent
↓
File application form and enclosures
↓
Registration section
↓
Technical committee for evaluation [TCE {1}]
↓
a] Pending for more information 
OR
b] Approved 
OR
c] Not Approved
↓
Analysis (Central laboratory for food and drug analysis)
↓
Technical committee for evaluation [TCE {2}]
↓
a] Pending for more information (Stop clock; up to the 
receipt of required information)
OR
b] Approved 
OR
c] Not Approved
↓
Pricing section
↓
Technical committee for evaluation [TCE {3}]
↓
Acceptance or non-acceptance
↓
Final approval or rejection
Stability data requirements[12]
SFDA recommends the GCC guidelines for stability study 
data preparation. GCC countries come under climatic 
Zone III and IVa (Hot and dry and hot and humid). 
Three primary batches are recommended by the GCC 
guidelines. For generic drug product long-term stability 
study supporting the complete proposed shelf-life should 
be submitted. 
KINGDOM OF BAHRAIN-DRUG REGISTRATION 
REQUIREMENTS[13]
The regulations for pharmaceutical registration in Bahrain 
are almost similar to the other GCC countries. All types of 
necessary information is required by the Ministry of Health, 
Bahrain but as compared to the other GCC countries, they 
also focus on the details of the company profile and several 
types of business activities like current business merger by 
the company, etc. The following table provides the basic 
information required for the registration of a drug in the 
Kingdom of Bahrain and other GCC countries.
KUWAIT: DRUG REGISTRATION REQUIREMENTS
Medicines in Kuwait are regulated for quality, safety and 
efficacy standards, price control, and patent protection. 
Kuwait has 40 years of experience of a regulatory system 
and plays a prominent role in the GCC. The Kuwait food 
and drug authority (KuFDA) is the head regulatory agency, 
which follows the ministerial decree 302/80 to register 
pharmaceutical products. 
According to Dr. Reem Al-Essa, Head of the Licensing 
Division of the Kuwait Drug and Food Control, “Kuwait 
is facing an overwhelming regulatory challenge reflecting 
the rapid advancement of the regulatory services with 
limited resources possibly influencing patients’ timely 
access to medicines.”[14] The Pharmaceutical manufacturing 
environment is not very competitive in Kuwait because 
of the very small population and the lack of the proper 
expertise to establish a good base of manufacturing 
practices for the pharmaceutical products within the 
country. There is only one manufacturing company 
(Kuwait-Saudi Pharmaceutical Industry Co- KSPICO) in 
Kuwait. This company produces generic medicines.
Enclosures required for drug registration in GCC 
countries[8,9]
The documents required to be submitted to fulfill different 
regulatory requirements for drug registration in GCC 
countries are summarized and compared in Table 5 and 6. 
Table 4: Target performance timelines[10]
Process Target performance 
timeline (days)
Marketing authorization (MA) application for 
generic drugs
165
Marketing authorization (MA) application for new 
chemical entity (NCEs)
290
Marketing authorization (MA) application for 
biologics
290
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Table 5: Drug registration requirements in Saudi Arabia, Bahrain, Kuwait and UAE
Saudi Arabia[8-10] Bahrain[13] Kuwait[15,16] UAE[17]
Format  CTD format. eCTD 
recommended.
Module 2 to 5: 
according to ICH 
CTD format.
Module 1: regional 
requirements:
•  Cover letter
•  Table of contents 
(ToC)
•  Application form
•  Product 
information: 
summary 
of product 
characteristics 
(SmPC), product 
information leaflet 
(PIL) and labeling 
– all in WHO 
template format.
•  Information on 
experts involved 
in clinical, non- 
clinical studies.
•  Environment risk 
assessment.
•  Pharmacovigilance
•  Certificate of 
pharmaceutical 
product (CoPP)  
•  Pricing 
•  Response to 
questions asked by 
SFDA (in any)
General 
information
•  Company profile
•  Number of 
manufacturing sites 
owned by company
•  Address of each site
•  Legal and commercial 
relations with all sites
•  Manufacturing license 
with date in country of 
origin (COO).
•  Address of applicant 
with contact details.
•  GMP certificate from 
country of origin.
•  Number of employees 
in different section 
and their qualification 
details.
•  Graphic design and 
flow of manufacturing 
line of site.
•  List of all products 
manufactured at 
company’s site or 
contract manufacturing 
organization (if any) 
or other marketing 
authorization holder 
(MAH).
•  Relationship with 
MAHs.
•  Any previous 
inspection by GCC 
health authorities or 
Arab health authorities.
Information 
required
•  Reference 
standard with 
CoA.
•  Finished 
product 
sample.
•  Patient 
information 
leaflet (English 
and Arabic).
•  Source of 
supply of API 
and inactive 
ingredients.
•  Raw material 
specifications.
•  Finished 
products’ 
specifications 
with quality 
control 
methods.
•  Stability data:
•  Long term- 
three batches 
(two pilot 
and one 
production).
•  Accelerated 
studies: six 
months, same 
three batches, 
used for long-
term studies.
•  Bioequiva-
lence study 
data.
Administrative 
information
•  Distributor 
of product in 
UAE.
•  Manufacturing 
site.
•  Marketing 
authorization 
holder and 
power of 
attorney.
•  Manufacturer 
of API.
•  Regulatory 
status.
•  Price list.
•  Declaration 
(In accordance 
with the 
medicines’ 
regulations of 
Drug Control 
Department- 
Ministry of 
Health -UAE)
Presentation a. Hard copy: 
  Bounded in a ring 
binder (A4 size, 2 
ring binders). Not 
more than 300 pages 
in each binder.
Information 
to Ministry 
of Health 
authorities
MOH authorities should be 
informed about any sale, 
merge, takeover or any 
legal or commercial action 
concerning the company or 
its site within 90 days of the 
action.
Certificates •  WHO-CoPP.
•  CoA.
•  Certificate of 
suitability for 
TSE free  
product.
•  Legalized price 
list.
•  Certificate of 
alcohol  
content.
•  Composition 
certificate.
•  List of countries 
where product  
has been 
registered.
Five countries have been taken for the comparison. They 
are Saudi Arabia, UAE, Oman, Bahrain, and Kuwait.
CONCLUSION
The GCC market is very lucrative in terms of benefits 
offered to the Indian pharmaceutical industry. With large 
pharmaceutical markets like the US, Europe and Japan 
getting saturated, it is the need of the hour that the Indian 
pharmaceutical industry in general and pharmaceutical 
companies in particular tap the opportunity of this 
“emerging” GCC market.
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Table 5: Contd...
Saudi Arabia[8-10] Bahrain[13] Kuwait[15,16] UAE[17]
b. Soft copy:
  CD-ROM/ DVD.
  Two soft copies 
and one hard 
copy. (For NCE, 
biologics and 
biosimilars- only 
module 1, 2 and 3 
in hard copy).
  Media should be 
autostartable and 
not be bootable. 
Must be ‘virus-
free’ and must 
not be password-
protected.
  Language- English 
or Arabic.
Product 
description
•  Number of submitted 
files.
•  Number of submitted 
samples.
•  Table of content 
(index) of submitted 
files.
Product 
dossier
Drug product 
information.
Packaging, 
patient 
information 
leaflet, labeling.
Storage condition 
and shelf-life.
Composition.
Ingredients of 
animal origin.
Leaflet 
information.
Pharmacological 
properties.
Bioequivalence 
details for 
generic product
Certificates Authenticated by the 
Ministry of health of 
the country of origin 
and additionally 
by Saudi Arabian 
embassy.
Following 
Certificates required:
•  CoPP/ free sale 
certificate.
•  CoA.
•  Pork-free 
declaration.
•  Price list.
Contents of 
file
•  WHO-certificate of 
pharmaceutical product 
(CoPP) issued by 
country of origin and 
legalized by any one 
GCC embassy.
•  Summary of product 
characteristics (SmPC).
•  Separate file for quality 
control laboratory 
including all quality 
data and information 
e.g. certificate of 
analysis, validation 
report etc.
•  Full description about 
API, and excipients 
excipients.
•  Description about 
vehicles and carriers 
used.
•  Method of 
manufacturing.
•  Name and address of 
involved CROs (if 
any).
•  Description of outer 
pack and accessories 
used.
•  Concentration of 
product (per unit mass 
or volume).
•  Source of starting 
material.
•  Proposed label.
•  Product patient leaflet 
(Arabic/English).
•  Toxicological data 
(for NCE and newly 
introduced generic 
drugs only).
•  Bioequivalence study 
reports (for generic 
drug registration).
•  Animal source (if any).
•  Price certificate 
authenticated by health 
authorities of country 
of origin.
Pateriya, et al.: Regulatory aspects of pharmaceutical exports in GCCJournal of Young Pharmacists Vol 3 / No 2  161
Table 6: Enclosures required for drug registration in five Gulf Cooperation Council countries
Sr. no. Enclosures Saudi Arabia Kuwait Uae Oman Bahrain
1 Control specification and method of analysis R R R R NR
2 Certificate of analysis attested by health authority and country of origin (CoO) R NR R NR NR
3 Legalized free sale certificate issued by health authorities of CoO, indicating that 
product is registered and marketed with same name and composition.
R R R R R
4 Legalized certificate indicating that diluents used are allowed to be used in  CoO R NR NR NR R
5 Legalized price certificate issued by competent authority of  CoO  and attested by 
embassy including ex-factory price, wholesale price in  CoO
R R R NR R
6 Retail/ public price in CoO R NR R NR R
7 Export price to country and neighboring countries R NR R NR R
8 Stability studies in various defined conditions R R R R R
9 Storage conditions R R R R R
10 Name of developed countries in which the product is registered R R R R R
11 Abstract from scientific references about product R R R R R
12 Sealed sample of product and copies of label R R R R R
13 Quantity specified for each pack and outer pack of product R R NR NR R
14 Leaflet in Arabic and English, including;
A.  Name of product R R R R R
B. Composition  R R R R R
C.  Mode of action R R R R R
D. Effect R R NR R R
E. Indications R R NR NR R
F. Contraindications  R R NR R R
G. Precautions R R NR R R
H. ADR R R NR R R
I. Antidote R R NR NR R
J.  Dosage and administration R NR NR R R
15 Product labeling R R R R R
16 Bioavailability studies R R R R R
17 Scientific basis of justifying the formulation of combination product R R R NR NR
18 Post marketing surveillance R NR NR NR NR
19 Certificate of sterility and pyrogen free pharmaceutical product NR R R NR NR
20 Copy of reference pharmacopoeia R R R NR NR
21 CTD format for dossier submission R[9] NR NR NR NR
22 eCTD or NeeS (non eCTD electronic submission) R[9] NR NR NR NR
R: Recommended by regulatory authority, NR: Generally, not recommended by regulatory authority
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